anti-ACE2 (human), mAb (AC18F) (ATTO 647N)
Method: HepG2 cell line is treated with CellTase solution (Abeomics) before analysis and then stained with anti-ACE2 (h), mAb (AC18F) (ATTO 647N) (red line) or an isotype control, mouse IgG1 (ATTO 647N) (Prod. No. AG-35B-0003TS) (green line) at 1µg/10E6 cells each and then analyzed by flow cytometry.
|Synonyms||SARS Receptor; Angiotensin-converting Enzyme 2; ACEH; Metalloprotease MPROT15; SARS-CoV-2 Receptor|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant human ACE2.|
Flow Cytometry: (1:1'000)
Recognizes human ACE2. Does not detect recombinant human ACE2 that has a tag at the C-terminus of the protein.
|Purity Detail||Protein G-affinity purified.|
|Formulation||Liquid. In PBS.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Do not freeze.
Protect from light.
Keep conjugated formats at +4°C.
Stable for at least 1 year after receipt when stored at +4°C.
|Product Specification Sheet|
Angiotensin-converting enzyme2 (ACE2) is an ectoenzyme (carboxypeptidase) with an extracellular catalytic domain that predominantly localizes at the plasma membrane and is thereby able to hydrolyze circulating peptides. ACE2 has approximately 42% sequence identity with ACE, and its cytoplasmic and transmembrane domains show 48% homology to the protein collectrin that plays a critical role in the amino acid absorption of the kidney. ACE2 converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. ACE2 is involved in the regulation of systemic blood pressure and has direct effects on cardiac functions. It is expressed predominantly in endothelial cells of the lung, gut, heart and kidney. ACE2 together with the protease TMPRSS2 acts as a functional receptor for SARS coronavirus as well as for the new highly pathogenic coronavirus, 2019-nCoV/SARS-CoV-2, which is cause for pneumonia COVID-19.
- Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34 positive cells in rabbit atherosclerotic plaques: A. Zulli, et al.; Exp. Physiol. 93, 564 (2008)
- Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications: VB. Patel, et al.; Clin. Sci. 126, 471 (2014)
- Syncytia formation by SARS-CoV-2-infected cells: J. Buchrieser, et al.; EMBO J. e106267 (2020)
- High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients: X. Song,et al.; bioRxiv (Preprint) (2020)